ArticleACS omega2022
Lipid-Coated Hybrid Nanoparticles for Enhanced Bacterial Biofilm Penetration and Antibiofilm Efficacy.
Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Optimized Chitosan Nanoparticles for Enhanced Ciprofloxacin Delivery and Activity Against Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Bacteria-Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Exploitation of cholesterol-dependent cytolysins for targeted biosensing and therapeutic systems.Drug delivery and translational research · 2026Review
- Ultrasound-Responsive Nanoparticles Enable Hydrophobic Antibiotic Release and Deep Penetration for Biofilm Treatment.JACS Au · 2026Article
- Electrically Charged Lipid Nanoparticles as Intracanal Antimicrobial Delivery Systems: A Narrative Review of Preclinical Evidence for Biofilm Control.Dentistry journal · 2026Review
- Dual Core-Shell Loaded Lipid-Polymer Hybrid Nanoparticles as Combination Anti-Infective Delivery Platforms.Pharmaceutics · 2025Article
- Therapeutic Approach Based on Nanotechnology with Chitosan-Coated Zein Nanoparticles Containing Quercetin Against ResistantPharmaceutics · 2025Article
- The Role of Nanoparticle Elasticity on Biological Hydrogel Penetration.Pharmaceutics · 2025Review
- Nanomaterials for the Treatment of Contamination by Nosocomial Pathogens in Intensive Care Units.International journal of nanomedicine · 2025Review
- Polymer-Lipid Hybrid Nanoparticles for Enhanced Gentamicin Efficacy Against Drug-Resistant Bacteria.Nanotechnology, science and applications · 2025Article
- Quorum Quenching Approaches against Bacterial-Biofilm-Induced Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Cubosome-carrying bacterial cellulose membrane as a versatile drug delivery platform.Materials today. Bio · 2024Article
- Recent advances in nanostructured delivery systems for vancomycin.Nanomedicine (London, England) · 2024Review
- Strategies for combating antibiotic resistance in bacterial biofilms.Frontiers in cellular and infection microbiology · 2024Review
- Organically Modified Mesoporous Silica Nanoparticles against Bacterial Resistance.Chemistry of materials : a publication of the American Chemical Society · 2023Review
- Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.Nanomaterials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to 80% of all infections are biofilm-mediated and they are often challenging to treat as the underlying bacterial cells can become 100- to 1000-fold more tolerant toward antibiotics. Antibiotic-loaded nanoparticles have gained traction as a potential drug delivery system to treat biofilm infections. In particular, lipid-coated hybrid nanoparticles (LCHNPs) were investigated on their capability to deliver antibiotics into biofilms. In this study, LCHNPs composed of a poly(lactic-co-glycolic acid) (PLGA) core and dioleoyl-3-trimethylammonium propane (DOTAP) lipid shell were developed and loaded with vancomycin (Van). In vitro antibacterial and antibiofilm tests were performed to evaluate the antimicrobial efficacy of the LCHNPs. LCHNPs were successfully fabricated with high vancomycin encapsulation and loading efficiencies, and exhibited enhanced antibacterial effects against planktonic
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.